Cervical cancer is a cancer that is developed in the cervix of women. It mainly affects women, who are sexually active, between the age of 30 and 45 years. There are no any symptoms that are visible in early stages of cervical cancer. Nevertheless, a screening procedure termed as Pap test (Papanicolaou test) is used to identify changes in the cervix before the cancer develops, which in turn leading to significant reduction in the death rate of cervical cancer. There are various kinds of cervical cancer including adenocarcinoma and squamous cell cancer, which are two main kinds of it.
Request for Analysis of COVID-19 Impact on Cervical Cancer Drugs Market –
There are various factors involved in boosting the growth of the cervical cancer drugs market. The U.S. Food and Drug Administration (FDA) increased its rate of drug approval for the treatment of cervical cancer, which in turn led to the market growth. For instance, Mvasi (bevacizumab-awwb) was approved by the U.S. Food and Drug Administration (FDA) in September 2017, for the treatment of multiple types of cancer including kidney cancer, brain, lung, and cervical colorectal. Mvasi is as biosimilar to Avastin (bevacizumab) that is used to treat metastatic, recurrent, or persistent cervical cancer. Moreover, Genentech’s Avastin was approved by U.S. FDA in August 2014. It is a bevacizumab solution that is combined with paclitaxel for the treatment of metastatic, recurrent, or persistent cervical cancer.
Other factors that are expected to foster the revenue growth of cervical cancer drugs market are raising number of new targeted cancer drugs, rising insurance coverage, and increasing investments for cancer research. For instance, in 2015, around US$ 4,480 million were invested by National Cancer Institute on research and development in various cancers including uterine cancer, cervical cancer, ovarian cancer, lung cancer, breast cancer, liver cancer, colorectal cancer and leukaemia. Moreover, around US$ 87.8 billion were invested by the American Cancer Society, U.S. in 2014 on cancer research, where around 44% of the major cost was paid by private insurance companies.
The lack of awareness regarding the diagnosis of invasive cancer for its prevention, along with increase in incidence of HIV in women and cervical cancer among the global population are responsible to propel the market growth. For Instance, in March 2018, around 22 grants, i.e., around US$ 9.3 million were funded by the American cancer Society for cervical cancer. The investment value is offered to a single or group of research focusing on an area of cancer or a specific kind of a cancer. For instance, in 2015, Cancer Research UK registered that, from 2013 to 2015, around 3,200 new cervical cancer cases were diagnosised in the UK annually.
Furthermore, in 2015, around 2% of all cancer cases in females are accounted to be cervical cancer in the UK. For Instance, in January 2018, the National Institute of Cancer Prevention and Research (NICPR) and the Associated Chambers of Commerce and Industry of India (ASSOCHAM) conducted a joint study conducted on cervical cancer. The study reported that about 17% of the all cancer deaths in women of age between 30 and 69 years are from India, which is about one fourth of the global cases. Furthermore, it is estimated that around 1 in 53 Indian women, during their lifetime, are anticipated to be diagnosed with cervical cancer.
Request PDF Brochure Report –
The valuation of the global cervical cancer drugs market has reached up to $7.92 billion in 2020. The market is estimated to grow at a CAGR of 2.1% and is expected to reach up to $8.09 billion in 2021.
The major players operating in the cervical cancer drugs market consist of Novartis AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Biocon Limited, Hetero, Allergan plc, GlaxoSmithKline plc, AstraZeneca plc, Eli Lilly and Company, Pfizer, Inc., and Alnylam Pharmaceuticals, Inc.
Some of the major market players aimed to enhance their market shares and retain their competence in the market by following more and more organic growth strategies. For instance, a biologics research and development division of AstraZeneca named as MedImmune collaborated with Advaxis for clinical trial in July 2014. Both the companies conducted a study on Phase I/II immunotherapy to estimate efficacy and safety of ADXS-HPV, a cancer immunotherapy vaccine of Advaxis and MEDI4736, an investigational anti-PD-L1 immune checkpoint inhibitor of MedImmune. The study was conducted for development of treatment in patients with refractory, recurrent or advanced cervical cancer associated with Human Papillomavirus (HPV).
The segmentation of the global cervical cancer drugs market on the basis of geographical area is carried out into North America, Latin America, Asia Pacific, Middle East, Africa and Europe. Among these regions, North America dominated the cervical cancer drugs market due to their growing research and development activities by various healthcare regulatory organizations and also their increasing incidences of cervical cancer in these regions. For instance, in 2018, the American Cancer Society’s (ACS) estimated the number of new cases that were diagnosed of invasive cervical cancer were around 13, 240 along with the death of around 4,170 women from cervical cancer. Moreover, in the U.S., a collaborative research projects with funds ranging from US$ 5,000-US $10,000 each was announced by Cervical Cancer-Free Coalition (CCFC) in 2013 to focus on cervical cancer treatment.
Reasons to Purchase this Report
Current and future of global Cervical Cancer Drugs market outlook in the developed and emerging markets
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/countries that are expected to witness the fastest growth rates during the forecast period
The latest developments, market shares, and strategies that are employed by the major market players
Buy This Complete A Business Report With Flat US $2000 Off @
Major Point Answered in Cervical Cancer Drugs Market Research Study are:
What will be the progress rate of the Cervical Cancer Drugs Market for the conjecture period, 2020-2027?
What are the prominent factors driving the Cervical Cancer Drugs Market across different regions?
Who are the major vendors dominating the Cervical Cancer Drugs industry and what are their winning strategies?
What will be the market scope for the estimated period?
What are the major trends shaping the expansion of the industry in the coming years?
What are the challenges faced by the Cervical Cancer Drugs Market?
Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027